Nuo Therapeutics, Inc. (AURX) stock
Close on Oct 19, 2026Market cap $60.99MP/E –Yield –
Nuo Therapeutics, Inc. grew revenue 166.6% to $5.20M over the twelve months to Jun 30, 2026. Free cash flow was -$2.45M. At the latest close the market valued the company at $60.99M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $60.99M
- P/E ratio
- –
- Price to sales
- 11.73
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -4.01%
Fundamentals
- Revenue
- $5.20M
- Net income
- -$2.01M
- EPS, diluted
- -$0.04
- Free cash flow
- -$2.45M
- Book value per share
- -$0.03
- Diluted shares
- 48M
Trading
- Previous close
- $1.30
- Open
- $1.28
- Day's range
- $1.25 – $1.30
- Volume
- 69,871
- Average volume (20 days)
- 10,396
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | AURX | S&P 500 | Difference | AURX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | +0.6% | −3.7 pts | ||
| 3 months | +26.0% | +3.4% | +22.6 pts | ||
| Year to date | -36.0% | +13.3% | −49.3 pts | ||
| 1 year | -49.6% | +16.6% | −66.2 pts | ||
| 3 years | +137.2% | +86.4% | +50.8 pts | +33.4% | +23.1% |
| 5 years | +2973.2% | +81.9% | +2891.3 pts | +98.4% | +12.7% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nuo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
About Nuo Therapeutics
Surgical & Medical Instruments & Apparatus
Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing cell-based biological therapies for chronic wound care. Its primary commercial product is the Aurix System, a point-of-care medical device that processes a patient's peripheral blood into an autologous platelet-rich plasma hematogel to facilitate tissue repair and healing in exuding wounds, such as diabetic foot ulcers. The company's customer base consists primarily of private practice physicians, hospital outpatient wound care clinics, and its distribution partner, Smith+Nephew, which distributes a private-label version of the product.
Company profile, executives and historyNuo Therapeutics stock: common questions
What is Nuo Therapeutics's stock price?
AURX closed at $1.26 on Oct 19, 2026, down 3.08% on the day.
What is Nuo Therapeutics's market cap?
Nuo Therapeutics was worth $60.99M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is AURX's P/E ratio?
Nuo Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
How much revenue does Nuo Therapeutics make?
Nuo Therapeutics reported revenue of $5.20M for the twelve months to Jun 30, 2026, up 166.6% from a year earlier.
Does Nuo Therapeutics pay a dividend?
No. Nuo Therapeutics has not paid a cash dividend over the last twelve months.
How has AURX stock performed over the past year?
Including dividends, AURX returned -49.6% over the past year, against +16.6% for the S&P 500.
Who are Nuo Therapeutics's competitors?
Companies most similar to Nuo Therapeutics by business, industry and size include CNSY, RNXT, TNON, XAIR, SINT.
See a number that looks wrong?